Rivaroxaban for treatment of pediatric venous thromboembolism. An Einstein-Jr phase 3 dose-exposure-response evaluation.

Guy Aaron YoungAnthonie W A LensingPaul MonagleChristoph MaleKirstin ThelenStefan WillmannJoseph S PalumboRiten KumarIldar NurmeevKerry HegeFanny BajollePhilip ConnorHélène L HooimeijerMarcela TorresAnthony K C ChanGili KenetSusanne HolzhauerAmparo SantamaríaPascal AmedroJan Beyer-WestendorfIda MartinelliM Patricia MassicotteWilliam T SmithScott D BerkowitzStephan SchmidtVictoria PriceMartin H PrinsDagmar Kubitzanull null

Published in: Journal of thrombosis and haemostasis : JTH (2020)

Based on this analysis and the recently documented similar efficacy and safety of rivaroxaban compared with standard anticoagulation, we conclude that bodyweight-adjusted pediatric rivaroxaban regimens with either tablets or suspension are validated and provide for appropriate treatment of children with VTE.

Keyphrases

venous thromboembolism
direct oral anticoagulants
atrial fibrillation
pulmonary embolism
childhood cancer